Anti-ICAM-1 antibody-modified nanostructured lipid carriers: a pulmonary vascular endothelium-targeted device for acute lung injury therapy

Abstract

BackgroundAcute lung injury (ALI) is a life-threatening clinical syndrome without effective treatment. Targeting delivery of glucocorticoid to lung shows potential efficacy for ALI based on their anti-inflammatory and anti-fibrotic properties, breaking through their clinical application limitation due to systemic side effects. This work was aimed to establish lung-targeted dexamethasone (DEX) loaded nanostructured lipid carriers (NLCs) with opposite surface charge and investigate their therapeutic effects on lipopolysaccharide (LPS)-induced ALI mice.ResultsThe diameter of anionic anti-intercellular adhesion molecule 1 (anti-ICAM-1) antibody-conjugated DEX-loaded NLCs (ICAM/DEX/NLCs) and the cationic ones with octadecylamine (ODA) modification (ICAM/DEX/ODA-NLCs) was about 249.9 and 235.9 nm. The zeta potential of ICAM/DEX/NLCs and ICAM/DEX/ODA-NLCs was about − 30.3 and 37.4 mV, respectively. Relative to the non-targeted control and ICAM/DEX/ODA-NLCs, ICAM/DEX/NLCs exhibited higher in vitro cellular uptake in LPS-activated human vascular endothelial cell line EAhy926 after CAM-mediated endocytosis, and stronger in vivo pulmonary distribution in the ALI model mice. In vivo i.v. administration of ICAM/DEX/NLCs significantly attenuated pulmonary inflammatory cells infiltration, and the production of pro-inflammatory cytokine TNF-α and IL-6 in ALI mice. H&E stain also revealed positive histological improvements by ICAM/DEX/NLCs.ConclusionsICAM/DEX/NLCs may represent a potential pulmonary endothelium targeted device, which facilitate translation of DEX into clinical ALI treatment.Electronic supplementary materialThe online version of this article (10.1186/s12951-018-0431-5) contains supplementary material, which is available to authorized users.

Tumor necrosis factor-α small interfering RNA alveolar epithelial cell-targeting nanoparticles reduce lung injury in C57BL/6J mice with sepsis

“… 31 – 33 Exogenous siRNAs must pass through the cell membrane and reach a sufficient concentration in the cytoplasm to successfully silence the expression of specific genes. 34 However, a safe and effective transport vector has become an important obstacle in the development of this. 35 Nanoparticles, as a new type of non-viral gene carrier, offer key advantages in gene delivery.…”

Humanized Bispecific Antibody (mPEG×HER2) Rapidly Confers PEGylated nanoaparticles Tumor Specificity for Multimodality Imaging in Breast Cancer

“…Without changing the structure of nanoparticles, the PEG-NPs Developing an easy method to produce targeted PEG-NPs against the various disease-associated markers is important for imaging. Chemical modification of antibodies on nanoparticles is currently a common method to confer targeting of a disease [20,21]. For example, Paulis et al coupled the anti-ICAM-1antibody to N-succinimidyl S-acetylthioacetate (SATA) to generate a free thiol group for conjugating with the maleimide-PEG-liposomal MRI contrast agent (L), and they proved that the binding of anti-ICAM-1 L on bEnd.5 endothelial cells could be 2-fold higher than that of L to monitor the inflammation-related ICAM-1expression on blood vessels [22].…”

Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer

“…Developing an easy method to produce targeted PEG-NPs against the various disease-associated markers is important for imaging. Chemical modification of antibodies on nanoparticles is currently a common method to confer targeting of a disease [20,21]. For example, Paulis et al coupled the anti-ICAM-1antibody to N-succinimidyl S-acetylthioacetate (SATA) to generate a free thiol group for conjugating with the maleimide-PEG-liposomal MRI contrast agent (L), and they proved that the binding of anti-ICAM-1 L on bEnd.5 endothelial cells could be twofold higher than that of L to monitor the inflammation-related ICAM-1expression on blood vessels [22].…”